AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25580989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Number of subjects: 67
Study 25580989 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline continuous wound infusion (CWI) at 5 ml/h after laparotomy or 2 ml/h after laparoscopy
Number of subjects: 67
Study 25580989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine CWI in laparotomy subgroup
Number of subjects: 67
Study 25580989 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline CWI in laparotomy subgroup
Number of subjects: 67
Study 25580989 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.38% ropivacaine CWI in laparoscopy subgroup
Number of subjects: 67
Study 25580989 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline CWI in laparoscopy subgroup
Number of subjects: 67
Study 23663813 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle Heart Failure Model (SHFM) score increase by 1 unit
Number of subjects: 0
Study 23663813 — intervention group
Group type: EXPERIMENTAL
Intervention: SHFM scores of 1 or 2
Number of subjects: 0
Study 21425884 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system 10-30 mg
Number of subjects: 0
Study 21425884 — intervention group
Group type: COMPARATOR
Intervention: Placebo transdermal system
Number of subjects: 0
Study 21425884 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system
Number of subjects: 0
Study 18417466 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic cotreatment
Number of subjects: 1229
Study 17055302 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombin-soaked gel foam
Number of subjects: 71
Study 17055302 — intervention group
Group type: EXPERIMENTAL
Intervention: Compressed gas lavage
Number of subjects: 71
Study 17055302 — intervention group
Group type: COMPARATOR
Intervention: Saline solution lavage with sponge drying
Number of subjects: 71
Study 16613264 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Quxie granule (FQG)
Number of subjects: 1402
Study 16613264 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 1402
Study 12930196 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 Hz vibration frequency
Number of subjects: 16
Study 12930196 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 Hz vibration frequency
Number of subjects: 16
Study 12930196 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 Hz vibration frequency
Number of subjects: 16
Study 12930196 — intervention group
Group type: COMPARATOR
Intervention: No vibrations
Number of subjects: 16
Study 10232417 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude of 8,000 m
Number of subjects: 8
Study 10232417 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrival at 5,000 m
Number of subjects: 8
Study 10232417 — intervention group
Group type: EXPERIMENTAL
Intervention: Arrival at 8,000 m
Number of subjects: 8
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization with the arm tied to the torso for three to four weeks after reduction
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a sling, discontinued after patient comfort
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Immobilization for various durations
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 12-22 years
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 23-29 years
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients aged 30-40 years
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with at least two recurrences during the first two or five years
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographs showing evident Hermodsson (Hill-Sachs) lesion
Number of subjects: 245
Study 8934481 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographs at ten-year follow-up
Number of subjects: 245
Study 2010899 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day diet containing greater than 150 g/d of carbohydrate (group I)
Number of subjects: 37
Study 2010899 — intervention group
Group type: COMPARATOR
Intervention: Normal dietary pattern without dietary preparation (group II)
Number of subjects: 37
Study 2010899 — intervention group
Group type: COMPARATOR
Intervention: Both groups (I and II)
Number of subjects: 37
Study 6121766 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam
Number of subjects: 12
Study 6121766 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg buspirone hydrochloride
Number of subjects: 12
Study 6121766 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg buspirone hydrochloride
Number of subjects: 12
Study 6121766 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 31819401 — intervention group
Group type: EXPERIMENTAL
Intervention: FF/UMEC/VI
Number of subjects: 0
Study 31819401 — intervention group
Group type: COMPARATOR
Intervention: FF/VI
Number of subjects: 0
Study 31819401 — intervention group
Group type: COMPARATOR
Intervention: UMEC/VI
Number of subjects: 0
Study 27422154 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3mg rhTSH stimulation before radioiodine therapy (group I)
Number of subjects: 32
Study 27422154 — intervention group
Group type: COMPARATOR
Intervention: Control group without stimulation (group II)
Number of subjects: 32
Study 25856740 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion-regulation therapy combined with cognitive group therapy ('Before and beyond')
Number of subjects: 71
Study 25856740 — intervention group
Group type: COMPARATOR
Intervention: Normal individual treatment
Number of subjects: 71
Study 24080287 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Hip Abduction (AHAbd) test
Number of subjects: 34
Study 24080287 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Straight Leg Raise (ASLR) test
Number of subjects: 34
Study 24080287 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during AHAbd and ASLR tests
Number of subjects: 34
Study 21212432 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with fludarabine and cyclophosphamide (FC)
Number of subjects: 1369
Study 21212432 — intervention group
Group type: COMPARATOR
Intervention: Fludarabine and cyclophosphamide (FC)
Number of subjects: 1369
Study 19519312 — intervention group
Group type: EXPERIMENTAL
Intervention: Music therapy
Number of subjects: 0
Study 17962427 — intervention group
Group type: EXPERIMENTAL
Intervention: C.E.R.A. 3.0 microg/kg
Number of subjects: 42
Study 15465578 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied to the left prefrontal cortex
Number of subjects: 0
Study 15465578 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS applied to the right prefrontal cortex
Number of subjects: 0
Study 11675939 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 429
Study 11675939 — intervention group
Group type: COMPARATOR
Intervention: Diuretic (trichlormethiazide)
Number of subjects: 429
Study 9133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 0
Study 9133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 9133508 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 0
Study 9133508 — intervention group
Group type: COMPARATOR
Intervention: Prazosin
Number of subjects: 0
Study 9133508 — intervention group
Group type: COMPARATOR
Intervention: Diltiazem
Number of subjects: 0
Study 9133508 — intervention group
Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 0
Study 7701044 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene (0.25 mg/kg cocaethylene base)
Number of subjects: 6
Study 7701044 — intervention group
Group type: COMPARATOR
Intervention: Cocaine (0.25 mg/kg cocaine base)
Number of subjects: 6
Study 2959665 — intervention group
Group type: EXPERIMENTAL
Intervention: Cobe CML oxygenator
Number of subjects: 19
Study 2959665 — intervention group
Group type: COMPARATOR
Intervention: Shiley S‐100 bubble oxygenator
Number of subjects: 19
Study 31170036 — intervention group
Group type: EXPERIMENTAL
Intervention: Error ABF
Number of subjects: 4
Study 31170036 — intervention group
Group type: COMPARATOR
Intervention: Full ABF
Number of subjects: 4
Study 27720499 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based caregiver-training program
Number of subjects: 129
Study 27720499 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training program)
Number of subjects: 129
Study 25794203 — intervention group
Group type: EXPERIMENTAL
Intervention: SGB
Number of subjects: 20
Study 25794203 — intervention group
Group type: COMPARATOR
Intervention: Sham
Number of subjects: 20
Study 23275278 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1040
Study 22230406 — intervention group
Group type: EXPERIMENTAL
Intervention: Neo-adjuvant chemotherapy with cisplatin and gemcitabine plus immunotherapy with PBMC and rIL-2
Number of subjects: 82
Study 22230406 — intervention group
Group type: COMPARATOR
Intervention: Neo-adjuvant chemotherapy with cisplatin and gemcitabine
Number of subjects: 82
Study 19799138 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient supplement
Number of subjects: 0
Study 19799138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16924981 — intervention group
Group type: EXPERIMENTAL
Intervention: Repair (n=20)
Number of subjects: 45
Study 16924981 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing of defective margins (n=23)
Number of subjects: 45
Study 16924981 — intervention group
Group type: EXPERIMENTAL
Intervention: Refurbishing (n=23)
Number of subjects: 45
Study 16924981 — intervention group
Group type: EXPERIMENTAL
Intervention: Replacement (n=23)
Number of subjects: 45
Study 16924981 — intervention group
Group type: COMPARATOR
Intervention: No-treatment (n=24)
Number of subjects: 45
Study 15689090 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose varicella vaccine
Number of subjects: 186
Study 15689090 — intervention group
Group type: COMPARATOR
Intervention: One-dose varicella vaccine
Number of subjects: 186
Study 14622777 — intervention group
Group type: EXPERIMENTAL
Intervention: 4030W92 (25 mg/day)
Number of subjects: 41
Study 14622777 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9444683 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic community
Number of subjects: 694
Study 9444683 — intervention group
Group type: COMPARATOR
Intervention: Community residences
Number of subjects: 694
Study 7624492 — intervention group
Group type: EXPERIMENTAL
Intervention: Levetiracetam (pyrrolidine derivative) as an antiepileptic concomitant drug
Number of subjects: 0
Study 2612406 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibonis
Number of subjects: 4
Study 2612406 — intervention group
Group type: COMPARATOR
Intervention: Diabinese
Number of subjects: 4
Study 140824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 11-1430 (0.1% lotion)
Number of subjects: 257
Study 140824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A acid (0.05% lotion)
Number of subjects: 257
Study 140824 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lotion alone)
Number of subjects: 257
Study 31495658 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodality stimulation combined with standard physiotherapy (therapy group)
Number of subjects: 12
Study 31495658 — intervention group
Group type: COMPARATOR
Intervention: Standard physiotherapy alone (control group)
Number of subjects: 12
Study 31640153 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 1 (supplementation before conception)
Number of subjects: 1465
Study 31640153 — intervention group
Group type: EXPERIMENTAL
Intervention: Arm 2 (supplementation late 1st trimester)
Number of subjects: 1465
Study 31640153 — intervention group
Group type: COMPARATOR
Intervention: Arm 3 (usual care)
Number of subjects: 1465
Study 27794487 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct skill training (n=22, 10 sessions as adjunct to usual inpatient rehabilitation)
Number of subjects: 43
Study 27794487 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided training (n=21, same dose)
Number of subjects: 43
Study 27794487 — intervention group
Group type: COMPARATOR
Intervention: Guided training
Number of subjects: 43
Study 25822465 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement
Number of subjects: 4516
Study 25822465 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical decompression and fusion
Number of subjects: 4516
Study 23335675 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg/day for 5 years
Number of subjects: 184460
Study 23335675 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day for 5 years
Number of subjects: 184460
Study 21076131 — intervention group
Group type: EXPERIMENTAL
Intervention: Homeopathic consultation
Number of subjects: 83
Study 20031731 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based local delivery of fluid paclitaxel after bare metal stent implantation (group I)
Number of subjects: 204
Study 20031731 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent implantation (group II)
Number of subjects: 204
Study 20031731 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (group III)
Number of subjects: 204
Study 20031731 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter-based local delivery of fluid paclitaxel (group I)
Number of subjects: 204
Study 17314736 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day (RLX)
Number of subjects: 123
Study 17314736 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day + 17beta‐estradiol 1 mg/day (RLX + E)
Number of subjects: 123
Study 14752071 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral fluoropyrimidines for 1 year
Number of subjects: 5233
Study 11096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Mupirocin treatment
Number of subjects: 102
Study 11096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of > or = 2 positive body sites
Number of subjects: 102
Study 11096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous receipt of fluoroquinolone
Number of subjects: 102
Study 11096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal mupirocin
Number of subjects: 102
Study 11096006 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level mupirocin resistance
Number of subjects: 102
Study 8956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Subarachnoid neostigmine 75 micrograms (1.5 mL)
Number of subjects: 40
Study 8956398 — intervention group
Group type: COMPARATOR
Intervention: Control group received 1.5 mL subarachnoid saline
Number of subjects: 40
Study 8956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received 15 mg (3 mL) of hyperbaric bupivacaine 0.5%
Number of subjects: 40
Study 8956398 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine group
Number of subjects: 40
Study 8956398 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 1414563 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal empowerment program
Number of subjects: 52
Study 1414563 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 52
Study 4055985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg m‐CPP, orally
Number of subjects: 15
Study 4055985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 28851788 — intervention group
Group type: EXPERIMENTAL
Intervention: Regional transarterial hypothermic infusion (cold saline at 15°C) administered through a microcatheter in the ipsilateral internal carotid artery after thrombectomy when no improvement in NIHSS score is observed.
Number of subjects: 7
Study 25361617 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (FiO2 = 0.11)
Number of subjects: 15
Study 25361617 — intervention group
Group type: COMPARATOR
Intervention: Normoxia (FiO2 = 0.21)
Number of subjects: 15
Study 23588685 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry-flavored lozenge (Strepsils® strawberry sugar free)
Number of subjects: 102
Study 23588685 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange-flavored lozenge (Strepsils® orange with vitamin C)
Number of subjects: 102
Study 21826881 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar TURP (Gyrus electro surgical system)
Number of subjects: 140
Study 21826881 — intervention group
Group type: COMPARATOR
Intervention: Open prostatectomy (OPSU)
Number of subjects: 140
Study 18679613 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein hydrolysate (WPH)
Number of subjects: 16
Study 18679613 — intervention group
Group type: COMPARATOR
Intervention: Whey protein isolate (WPI)
Number of subjects: 16
Study 17093155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX group; n = 18)
Number of subjects: 46
Study 17093155 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR group; n = 18)
Number of subjects: 46
Study 17093155 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle (HL control group; n = 10)
Number of subjects: 46
Study 17093155 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (EX group)
Number of subjects: 46
Study 17093155 — intervention group
Group type: EXPERIMENTAL
Intervention: Calorie restriction (CR group)
Number of subjects: 46
Study 17093155 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle (HL control group)
Number of subjects: 46
Study 14687901 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol treatment
Number of subjects: 0
Study 14687901 — intervention group
Group type: COMPARATOR
Intervention: Benzbromarone treatment
Number of subjects: 0
Study 11518893 — intervention group
Group type: COMPARATOR
Intervention: Single dose of 150 mg fluconazole
Number of subjects: 556
Study 11518893 — intervention group
Group type: EXPERIMENTAL
Intervention: Two sequential doses of 150 mg fluconazole given 3 days apart
Number of subjects: 556
Study 11518893 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dose fluconazole regimen
Number of subjects: 556
Study 11518893 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of fluconazole
Number of subjects: 556
Study 11518893 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole therapy
Number of subjects: 556
Study 9028935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rearranged TEL gene group (27 patients)
Number of subjects: 104
Study 9028935 — intervention group
Group type: COMPARATOR
Intervention: Germline TEL group (77 patients)
Number of subjects: 104
Study 8402802 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass ionomer cement (Chelon‐Fil‐Espe)
Number of subjects: 10
Study 8402802 — intervention group
Group type: COMPARATOR
Intervention: Composite (Silux)
Number of subjects: 10
Study 3947414 — intervention group
Group type: EXPERIMENTAL
Intervention: 750-rad lymphoid irradiation
Number of subjects: 20
Study 3947414 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000-rad lymphoid irradiation
Number of subjects: 20
Study 3276469 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined oral and parenteral antimicrobial prophylaxis
Number of subjects: 119
Study 3276469 — intervention group
Group type: COMPARATOR
Intervention: Parenteral antimicrobial prophylaxis
Number of subjects: 119
Study 29332419 — intervention group
Group type: EXPERIMENTAL
Intervention: EnergyPod™
Number of subjects: 0
Study 29332419 — intervention group
Group type: EXPERIMENTAL
Intervention: SleepWing™
Number of subjects: 0
Study 28910662 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-day clinical skills refresher course directed by nurse instructors
Number of subjects: 160
Study 28910662 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study 26412215 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed nuts (30 g/d) for 12 weeks
Number of subjects: 0
Study 26412215 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 23635898 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined written and verbal instructions
Number of subjects: 39
Study 23635898 — intervention group
Group type: COMPARATOR
Intervention: Written instructions only
Number of subjects: 39
Study 21590739 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein drink containing 30g of whey protein (n=109)
Number of subjects: 219
Study 21590739 — intervention group
Group type: COMPARATOR
Intervention: Placebo drink containing 2.1g of protein (n=110)
Number of subjects: 219
Study 19100110 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 101
Study 19100110 — intervention group
Group type: COMPARATOR
Intervention: Cutting balloon angioplasty followed by bare metal stents (CBA + BMS)
Number of subjects: 101
Study 16540953 — intervention group
Group type: COMPARATOR
Intervention: Oxygen catheter (6 L/min)
Number of subjects: 20
Study 16540953 — intervention group
Group type: COMPARATOR
Intervention: T-piece system (12 L/min)
Number of subjects: 20
Study 16540953 — intervention group
Group type: COMPARATOR
Intervention: CPAP system (10 cm H2O, 12 L/min)
Number of subjects: 20
Study 12880400 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon fibre reinforced carbon (CFRC) endodontic post cemented with a composite luting agent
Number of subjects: 18
Study 12880400 — intervention group
Group type: COMPARATOR
Intervention: Conventional prefabricated post (wrought precious alloy) cemented with zinc phosphate
Number of subjects: 18
Study 11025363 — intervention group
Group type: EXPERIMENTAL
Intervention: THL 120 mg t.i.d.
Number of subjects: 8
Study 11025363 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Control)
Number of subjects: 8
Study 8881951 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment for a minimum of 9 months
Number of subjects: 20
Study 8881951 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride treatment
Number of subjects: 20
Study 1411281 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg omeprazole daily
Number of subjects: 12
Study 1411281 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg famotidine daily
Number of subjects: 12
Study 1411281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12